Characteristics of achieving clinically important weight loss in two paediatric weight management interventions

Lauren Fiechtner1,2, Ines Castro1, Erika R Cheng3

  • 1Division of General Academic Pediatrics, Department of Pediatrics, MassGeneral Hospital for Children, Boston, Massachusetts, USA.

Pediatric Obesity
|March 18, 2021
PubMed

Insights

Younger children and those without severe obesity were more likely to achieve clinically important weight loss (CIWL) in paediatric weight management interventions (PWMIs). Reducing sugary beverage intake also positively impacted CIWL outcomes.

Area of Science:

  • Pediatric Endocrinology
  • Public Health Nutrition
  • Behavioral Medicine

Background:

  • Childhood obesity is a significant public health concern requiring effective interventions.
  • Paediatric weight management interventions (PWMIs) aim to improve health outcomes through lifestyle changes.
  • Identifying factors associated with successful weight loss is crucial for optimizing intervention strategies.

Purpose of the Study:

  • To investigate the characteristics and lifestyle behaviors linked to achieving clinically important weight loss (CIWL) in children undergoing PWMIs.
  • To analyze data from two large-scale paediatric weight management trials (STAR and Connect for Health).

Main Methods:

  • Analysis of 1010 children from the STAR and Connect for Health trials.
  • Definition of CIWL as a decrease in BMI z-score by ≥0.2 units over one year.
  • Log-binomial regression used to assess associations between child/household factors, lifestyle behaviors, and CIWL.

Main Results:

  • Children with severe obesity had a lower likelihood of achieving CIWL (RR: 0.68).
  • Older children (≥10 years) were less likely to achieve CIWL compared to younger children (RR: 0.56).
  • Consuming fewer than one sugary beverage daily was associated with a higher likelihood of achieving CIWL (RR: 1.36).

Conclusions:

  • Younger age, absence of severe obesity, and reduced sugary beverage consumption are key factors associated with successful CIWL in PWMIs.
  • Early intervention and targeted lifestyle modifications, such as reducing sugary drink intake, can enhance the effectiveness of PWMIs.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
90
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
83
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
115
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
87
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
83
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
77